| Followers | 227 |
| Posts | 13600 |
| Boards Moderated | 0 |
| Alias Born | 03/15/2013 |
Tuesday, September 24, 2024 4:50:03 PM
Looks like finally institutional dumping, it has been long overdue, this may be one of the worst bio scams in ages, this ceo was a total destruction in his last role to
Recent OCGN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:31:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:30:23 PM
- Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes • GlobeNewswire Inc. • 05/14/2026 08:30:00 PM
- Ocugen to Participate in Upcoming May Scientific and Investor Conferences • GlobeNewswire Inc. • 05/13/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 03:37:19 PM
- Ocugen Provides Business Update with First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/05/2026 12:32:54 PM
- Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes • GlobeNewswire Inc. • 05/05/2026 12:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:03:53 PM
- Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes • GlobeNewswire Inc. • 05/04/2026 08:01:51 PM
- Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results • GlobeNewswire Inc. • 04/29/2026 11:02:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 11:01:37 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 11:01:16 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 11:00:34 AM
- Ocugen to Present at April 2026 Investor and Industry Conferences • GlobeNewswire Inc. • 04/23/2026 11:02:00 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/20/2026 09:18:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:56:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 01:26:46 AM
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 04/01/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 04:02:11 PM
- Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 03/24/2026 11:45:00 AM
- Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy • GlobeNewswire Inc. • 03/23/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 12:00:18 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:27:38 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/04/2026 05:23:26 PM
